Omega Laboratories Reports Completion of Method Validation with Cannabix Technologies Inc. for Marijuana Breath Detection
Omega Laboratories has successfully completed method validation for a marijuana breath test using Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) Breath Collection Unit (BCU). The validated test method can simultaneously quantify THC, Δ-8-THC, CBD, and CBN in breath aerosols.
The Cannabix BCU features advanced capabilities including start-up air flow self-check, ambient air sample collection, split sample A/B configuration, and anti-cheating mechanisms. The system utilizes mass spectrometry for analysis, ensuring high forensic standards.
This breakthrough enables detection of recent marijuana use (within minutes to several hours), addressing limitations of traditional testing methods that detect usage over extended periods. Omega Laboratories is now incorporating breath testing into its service offerings, positioning the partnership as a leading solution for employers facing challenges with cannabis detection in various industries including law enforcement, workplace safety, and healthcare.
Omega Laboratories ha completato con successo la validazione del metodo per un test del respiro per la marijuana utilizzando l'unità di raccolta del respiro (BCU) di Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF). Il metodo di test validato può quantificare simultaneamente THC, Δ-8-THC, CBD e CBN negli aerosol del respiro.
La Cannabix BCU presenta capacità avanzate, tra cui il controllo automatico del flusso d'aria all'avvio, la raccolta di campioni d'aria ambientale, la configurazione del campione diviso A/B e meccanismi anti-frode. Il sistema utilizza la spettrometria di massa per l'analisi, garantendo elevati standard forensi.
Questa innovazione consente di rilevare l'uso recente di marijuana (nell'arco di pochi minuti a diverse ore), affrontando le limitazioni dei metodi di test tradizionali che rilevano l'uso su periodi prolungati. Omega Laboratories sta ora integrando i test del respiro nelle sue offerte di servizi, posizionando la partnership come una soluzione leader per i datori di lavoro che affrontano sfide con la rilevazione della cannabis in vari settori, tra cui forze dell'ordine, sicurezza sul lavoro e sanità.
Omega Laboratories ha completado con éxito la validación del método para una prueba de aliento de marihuana utilizando la Unidad de Recolección de Aliento (BCU) de Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF). El método de prueba validado puede cuantificar simultáneamente THC, Δ-8-THC, CBD y CBN en aerosoles de aliento.
La Cannabix BCU cuenta con capacidades avanzadas, incluyendo auto-verificación del flujo de aire al inicio, recolección de muestras de aire ambiental, configuración de muestra dividida A/B y mecanismos anti-fraude. El sistema utiliza espectrometría de masas para el análisis, asegurando altos estándares forenses.
Este avance permite la detección de uso reciente de marihuana (dentro de minutos a varias horas), abordando las limitaciones de los métodos de prueba tradicionales que detectan el uso durante períodos prolongados. Omega Laboratories ahora está incorporando pruebas de aliento en su oferta de servicios, posicionando la asociación como una solución líder para los empleadores que enfrentan desafíos con la detección de cannabis en diversas industrias, incluyendo la aplicación de la ley, la seguridad en el trabajo y la atención médica.
오메가 연구소는 캐나빅스 테크놀로지스 Inc. (CSE: BLO) (OTC: BLOZF)의 호흡 샘플 수집 장치(BCU)를 사용하여 마리화나 호흡 테스트의 방법 검증을 성공적으로 완료했습니다. 검증된 테스트 방법은 호흡 에어로졸에서 THC, Δ-8-THC, CBD 및 CBN을 동시에 정량화할 수 있습니다.
캐나빅스 BCU는 시작 공기 흐름 자가 점검, 주변 공기 샘플 수집, 분할 샘플 A/B 구성 및 반칙 방지 메커니즘을 포함한 고급 기능을 제공합니다. 이 시스템은 분석을 위해 질량 분석법을 사용하여 높은 법의학 기준을 보장합니다.
이 혁신은 최근 마리화나 사용(몇 분에서 몇 시간 이내)을 감지할 수 있게 해주며, 장기간 사용을 감지하는 전통적인 테스트 방법의 한계를 해결합니다. 오메가 연구소는 이제 호흡 테스트를 서비스 제공에 통합하여, 법 집행, 직장 안전 및 의료를 포함한 다양한 산업에서 대마초 감지 문제에 직면한 고용주를 위한 선도적인 솔루션으로 파트너십을 포지셔닝하고 있습니다.
Omega Laboratories a réussi à valider une méthode pour un test de respiration de marijuana en utilisant l'unité de collecte de souffle (BCU) de Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF). La méthode de test validée peut quantifier simultanément le THC, le Δ-8-THC, le CBD et le CBN dans les aérosols de respiration.
La Cannabix BCU dispose de capacités avancées, notamment une auto-vérification du flux d'air au démarrage, la collecte d'échantillons d'air ambiant, une configuration d'échantillon divisé A/B et des mécanismes anti-triche. Le système utilise la spectrométrie de masse pour l'analyse, garantissant des normes judiciaires élevées.
Cette avancée permet la détection d'une consommation récente de marijuana (dans les minutes à plusieurs heures), abordant les limites des méthodes de test traditionnelles qui détectent l'utilisation sur de longues périodes. Omega Laboratories intègre désormais les tests de respiration dans ses offres de services, positionnant le partenariat comme une solution de premier plan pour les employeurs confrontés à des défis de détection du cannabis dans divers secteurs, y compris les forces de l'ordre, la sécurité au travail et la santé.
Omega Laboratories hat erfolgreich die Methodenvalidierung für einen Marihuana-Atemtest mit der Atemsammlungseinheit (BCU) von Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) abgeschlossen. Die validierte Testmethode kann THC, Δ-8-THC, CBD und CBN in Atemaerosolen gleichzeitig quantifizieren.
Die Cannabix BCU bietet fortschrittliche Funktionen, darunter eine Selbstprüfung des Luftstroms beim Start, die Sammlung von Umgebungsluftproben, eine A/B-Konfiguration für geteilte Proben und Anti-Betrugsmechanismen. Das System nutzt die Massenspektrometrie für die Analyse und gewährleistet hohe forensische Standards.
Dieser Durchbruch ermöglicht die Erkennung des kürzlichen Marihuanakonsums (innerhalb von Minuten bis mehreren Stunden) und behebt die Einschränkungen traditioneller Testmethoden, die den Konsum über längere Zeiträume erkennen. Omega Laboratories integriert nun Atemtests in sein Dienstleistungsangebot und positioniert die Partnerschaft als führende Lösung für Arbeitgeber, die mit Herausforderungen bei der Cannabisdetektion in verschiedenen Branchen, einschließlich Strafverfolgung, Arbeitssicherheit und Gesundheitswesen, konfrontiert sind.
- Successful method validation completed for marijuana breath test
- Technology enables detection of recent use (minutes to hours) vs. traditional methods (days to months)
- Partnership with established laboratory enhances market credibility
- Advanced anti-cheating features integrated into collection system
- Commercial implementation timeline not specified
- Market adoption and revenue potential unclear
VANCOUVER, British Columbia, March 18, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports the following news release was issued by Omega Laboratories, Inc. today.
MOGADORE, Ohio, March 18, 2025 -- Omega Laboratories, a leading drug testing laboratory renowned for its comprehensive services, proudly announces the development and validation of a marijuana breath test. This validation includes a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix Technologies’ Breath Collection Unit (BCU). This establishes Omega and Cannabix as the premier technology for collecting and testing breath for recent marijuana usage. This method validation marks a significant milestone in the pursuit of innovative solutions for drug testing and safety assurance.
Cannabix Technologies Inc. and Omega have collaborated to optimize the design of the Cannabix BCU and compact Breath Cartridge technology. The BCU includes a start-up unit air flow self-check, the ability to collect an ambient air sample to rule out external contamination from the immediate surrounding area, a split sample configured Breath Cartridge to simultaneously collect an A and B sample, and a collection system that will stop drawing in air should the donor stop breathing into the device. This prevents the device from pulling in ambient air from the surrounding area and a donor from trying to cheat the collection. The Cannabix BCU is at the forefront of advanced breath collection tools to collect breath accurately and non-invasively.
Omega Laboratories is currently in the process of incorporating breath testing into its suite of services. With credible and extensive research backing Cannabix's technology, including validation studies demonstrating its efficacy, Omega Laboratories is confident in the reliability and accuracy of the THC breath test system. In partnership with Cannabix, Omega has completed a full validation study that will be published to further demonstrate the effectiveness of the breath testing system in real-world testing scenarios. This will ensure unparalleled accuracy and reliability for clients.
"At Cannabix Technologies, we are thrilled with the method validation results from Omega Laboratories, a company that upholds a tradition of excellence in drug testing, backed by their extensive accreditations and certifications," stated, Rav Mlait, CEO of Cannabix Technologies Inc. "This partnership success further solidifies our commitment to providing trusted and highly accredited solutions, offering unparalleled expertise and reliability to future clients."
The integration of Cannabix's THC BCU technology with Omega Laboratories' testing protocols will enable rapid and precise detection of THC levels in breath samples. This innovative approach not only streamlines the testing process but also ensures reliable results for clients across various industries, including law enforcement, workplace safety, and healthcare.
Furthermore, as part of this collaboration, all breath samples analyzed by Omega Laboratories undergo a testing process using mass spectrometry (mass spec), a gold standard in analytical chemistry to confirm which analytes are present. This meticulous approach reinforces Omega's commitment to maintaining the highest forensic standards of quality and integrity.
With the rise in cannabis legalization, employers face new challenges in detecting recent use of marijuana. Traditional cannabis testing methods, such as oral fluid, urine, and hair tests, can detect cannabis use for extended periods, ranging from days to months. The premier solution for recent use detection will be utilizing the Cannabix BCU to collect breath then sending the sample to Omega for analysis. Omega will then detect if there was recent THC usage (minutes to several hours).
"Our partnership with Cannabix Technologies underscores our commitment to staying at the forefront of advancements in drug testing technology," said Bill Corl, CEO of Omega Laboratories. "By incorporating their groundbreaking THC breath collection technology, we are poised to enhance the accuracy, efficiency, and accessibility of cannabis testing."
About Omega Laboratories, Inc.
Omega Laboratories, headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Ontario, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 24 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine and Breath specimens. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless Custody & Control Form system (oCCF) in fourteen languages, licensure of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers new laboratories in countries that have demand for local service providers.
Omega Laboratories, Inc Contact: For additional information on these solutions, please contact Omega at 1-800-665-5569 or sales@omegalabs.net.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath testing technologies for a range of workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of the Breath Logix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
FAQ
What is the detection window for Cannabix Technologies' (BLOZF) marijuana breath test?
What compounds can Cannabix Technologies' (BLOZF) breath test detect?
What security features does the Cannabix (BLOZF) Breath Collection Unit include?
How does Omega Laboratories analyze the Cannabix (BLOZF) breath samples?
